Cargando…

Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1

STUDY OBJECTIVES: The diagnosis of narcolepsy type 1 (NT1) is based upon the presence of cataplexy and/or a cerebrospinal fluid (CSF) hypocretin-1/orexin-A level ≤ 110 pg/mL. We determined the clinical and diagnostic characteristics of patients with intermediate hypocretin-1 levels (111–200 pg/mL) a...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Hoeven, Adrienne Elisabeth, Fronczek, Rolf, Schinkelshoek, Mink Sebastian, Roelandse, Frederik Willem Cornelis, Bakker, Jaap Adriaan, Overeem, Sebastiaan, Bijlenga, Denise, Lammers, Gert Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113791/
https://www.ncbi.nlm.nih.gov/pubmed/35554594
http://dx.doi.org/10.1093/sleep/zsac052
_version_ 1784709645767540736
author van der Hoeven, Adrienne Elisabeth
Fronczek, Rolf
Schinkelshoek, Mink Sebastian
Roelandse, Frederik Willem Cornelis
Bakker, Jaap Adriaan
Overeem, Sebastiaan
Bijlenga, Denise
Lammers, Gert Jan
author_facet van der Hoeven, Adrienne Elisabeth
Fronczek, Rolf
Schinkelshoek, Mink Sebastian
Roelandse, Frederik Willem Cornelis
Bakker, Jaap Adriaan
Overeem, Sebastiaan
Bijlenga, Denise
Lammers, Gert Jan
author_sort van der Hoeven, Adrienne Elisabeth
collection PubMed
description STUDY OBJECTIVES: The diagnosis of narcolepsy type 1 (NT1) is based upon the presence of cataplexy and/or a cerebrospinal fluid (CSF) hypocretin-1/orexin-A level ≤ 110 pg/mL. We determined the clinical and diagnostic characteristics of patients with intermediate hypocretin-1 levels (111–200 pg/mL) and the diagnostic value of cataplexy characteristics in individuals with central disorders of hypersomnolence. METHODS: Retrospective cross-sectional study of 355 people with known CSF hypocretin-1 levels who visited specialized Sleep-Wake Centers in the Netherlands. For n = 271, we had full data on cataplexy type (“typical” or “atypical” cataplexy). RESULTS: Compared to those with normal hypocretin-1 levels (>200 pg/mL), a higher percentage of individuals with intermediate hypocretin-1 levels had typical cataplexy (75% or 12/16 vs 9% or 8/88, p < .05), and/or met the diagnostic polysomnographic (PSG) and Multiple Sleep Latency Test (MSLT) criteria for narcolepsy (50 vs 6%, p < .001). Of those with typical cataplexy, 88% had low, 7% intermediate, and 5% normal hypocretin-1 levels (p < .001). Atypical cataplexy was also associated with hypocretin deficiency but to a lesser extent. A hypocretin-1 cutoff of 150 pg/mL best predicted the presence of typical cataplexy and/or positive PSG and MSLT findings. CONCLUSION: Individuals with intermediate hypocretin-1 levels or typical cataplexy more often have outcomes fitting the PSG and MSLT criteria for narcolepsy than those with normal levels or atypical cataplexy. In addition, typical cataplexy has a much stronger association with hypocretin-1 deficiency than atypical cataplexy. We suggest increasing the NT1 diagnostic hypocretin-1 cutoff and adding the presence of clearly defined typical cataplexy to the diagnostic criteria of NT1. Clinical trial information: This study is not registered in a clinical trial register, as it has a retrospective database design.
format Online
Article
Text
id pubmed-9113791
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91137912022-05-18 Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1 van der Hoeven, Adrienne Elisabeth Fronczek, Rolf Schinkelshoek, Mink Sebastian Roelandse, Frederik Willem Cornelis Bakker, Jaap Adriaan Overeem, Sebastiaan Bijlenga, Denise Lammers, Gert Jan Sleep Neurological Disorders STUDY OBJECTIVES: The diagnosis of narcolepsy type 1 (NT1) is based upon the presence of cataplexy and/or a cerebrospinal fluid (CSF) hypocretin-1/orexin-A level ≤ 110 pg/mL. We determined the clinical and diagnostic characteristics of patients with intermediate hypocretin-1 levels (111–200 pg/mL) and the diagnostic value of cataplexy characteristics in individuals with central disorders of hypersomnolence. METHODS: Retrospective cross-sectional study of 355 people with known CSF hypocretin-1 levels who visited specialized Sleep-Wake Centers in the Netherlands. For n = 271, we had full data on cataplexy type (“typical” or “atypical” cataplexy). RESULTS: Compared to those with normal hypocretin-1 levels (>200 pg/mL), a higher percentage of individuals with intermediate hypocretin-1 levels had typical cataplexy (75% or 12/16 vs 9% or 8/88, p < .05), and/or met the diagnostic polysomnographic (PSG) and Multiple Sleep Latency Test (MSLT) criteria for narcolepsy (50 vs 6%, p < .001). Of those with typical cataplexy, 88% had low, 7% intermediate, and 5% normal hypocretin-1 levels (p < .001). Atypical cataplexy was also associated with hypocretin deficiency but to a lesser extent. A hypocretin-1 cutoff of 150 pg/mL best predicted the presence of typical cataplexy and/or positive PSG and MSLT findings. CONCLUSION: Individuals with intermediate hypocretin-1 levels or typical cataplexy more often have outcomes fitting the PSG and MSLT criteria for narcolepsy than those with normal levels or atypical cataplexy. In addition, typical cataplexy has a much stronger association with hypocretin-1 deficiency than atypical cataplexy. We suggest increasing the NT1 diagnostic hypocretin-1 cutoff and adding the presence of clearly defined typical cataplexy to the diagnostic criteria of NT1. Clinical trial information: This study is not registered in a clinical trial register, as it has a retrospective database design. Oxford University Press 2022-03-07 /pmc/articles/PMC9113791/ /pubmed/35554594 http://dx.doi.org/10.1093/sleep/zsac052 Text en © Sleep Research Society 2022. Published by Oxford University Press on behalf of the Sleep Research Society. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Neurological Disorders
van der Hoeven, Adrienne Elisabeth
Fronczek, Rolf
Schinkelshoek, Mink Sebastian
Roelandse, Frederik Willem Cornelis
Bakker, Jaap Adriaan
Overeem, Sebastiaan
Bijlenga, Denise
Lammers, Gert Jan
Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1
title Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1
title_full Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1
title_fullStr Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1
title_full_unstemmed Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1
title_short Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1
title_sort intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1
topic Neurological Disorders
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113791/
https://www.ncbi.nlm.nih.gov/pubmed/35554594
http://dx.doi.org/10.1093/sleep/zsac052
work_keys_str_mv AT vanderhoevenadrienneelisabeth intermediatehypocretin1cerebrospinalfluidlevelsandtypicalcataplexytheirsignificanceinthediagnosisofnarcolepsytype1
AT fronczekrolf intermediatehypocretin1cerebrospinalfluidlevelsandtypicalcataplexytheirsignificanceinthediagnosisofnarcolepsytype1
AT schinkelshoekminksebastian intermediatehypocretin1cerebrospinalfluidlevelsandtypicalcataplexytheirsignificanceinthediagnosisofnarcolepsytype1
AT roelandsefrederikwillemcornelis intermediatehypocretin1cerebrospinalfluidlevelsandtypicalcataplexytheirsignificanceinthediagnosisofnarcolepsytype1
AT bakkerjaapadriaan intermediatehypocretin1cerebrospinalfluidlevelsandtypicalcataplexytheirsignificanceinthediagnosisofnarcolepsytype1
AT overeemsebastiaan intermediatehypocretin1cerebrospinalfluidlevelsandtypicalcataplexytheirsignificanceinthediagnosisofnarcolepsytype1
AT bijlengadenise intermediatehypocretin1cerebrospinalfluidlevelsandtypicalcataplexytheirsignificanceinthediagnosisofnarcolepsytype1
AT lammersgertjan intermediatehypocretin1cerebrospinalfluidlevelsandtypicalcataplexytheirsignificanceinthediagnosisofnarcolepsytype1